Clinical characteristics and survival were compared in three groups: 259 PSA screened patients, 99 PSA screened patients with later diagnosis, and 626 clinically diagnosed prostatic adenocarcinoma patients. Here, KLK3 is linked to prostate adenocarcinoma.